Lesson plan

Ganaplacide

Ganaplacide (development codename KAF156) is a drug in development by Novartis for the purpose of treating malaria. It is a imidazolopiperazine derivative. It has shown activity against the Plasmodium falciparum and Plasmodium vivax forms of the malaria parasite.

Back to article

Article summary

Ganaplacide (development codename KAF156) is a drug in development by Novartis for the purpose of treating malaria. It is a imidazolopiperazine derivative. It has shown activity against the Plasmodium falciparum and Plasmodium vivax forms of the malaria parasite.

Key claims

No claims recorded.

Discussion questions

  1. Summarise the article in your own words. Which single claim would you verify first, and why?
  2. Which claim in this article is most likely to be revised as the sources update? How would you check its current status?
  3. If two sources disagreed about one of these facts, what would you need in order to trust one over the other?

Bibliography

No sources recorded.

Key claims and bibliography are generated from the same tracked claims and sources as the article page.